Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KZR Kezar Life Sciences Inc
- Stocks
- Healthcare
- NASDAQ: KZR
Price (delayed)
$4.22
Market cap
$30.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.49
Enterprise value
$5.26M
Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule
Highlights
The EPS is up by 18% year-on-year and by 13% since the previous quarter
The net income has grown by 18% YoY and by 13% from the previous quarter
KZR's revenue has dropped by 100% year-on-year
Kezar Life Sciences's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of KZR
Market
Valuations
Earnings
Shares outstanding
7.31M
Market cap
$30.83M
Enterprise value
$5.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$90.61M
Net income
-$83.74M
EBIT
-$82.14M
EBITDA
-$81.1M
Free cash flow
-$74.24M
Per share
Balance sheet
Liquidity
EPS
-$11.49
EPS diluted
-$11.49
Free cash flow per share
-$10.18
Book value per share
$16.02
Revenue per share
$0
TBVPS
$19.85
Total assets
$144.68M
Total liabilities
$27.77M
Debt
$16.18M
Equity
$116.92M
Working capital
$117.16M
Debt to equity
0.14
Current ratio
6.76
Quick ratio
6.51
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.7%
Return on equity
-58.7%
Return on invested capital
-60.3%
Return on capital employed
-66.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KZR stock price
How has the Kezar Life Sciences stock price performed over time
Intraday
2.43%
1 week
-6.22%
1 month
2.93%
1 year
-48.35%
YTD
-37.2%
QTD
-13.52%
Financial performance
How have Kezar Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$90.61M
Net income
-$83.74M
Gross margin
N/A
Net margin
N/A
KZR's revenue has dropped by 100% year-on-year
Kezar Life Sciences's gross profit has shrunk by 100% YoY
The company's operating income rose by 19% YoY and by 13% QoQ
The net income has grown by 18% YoY and by 13% from the previous quarter
Price vs fundamentals
How does KZR's price correlate with its fundamentals
Growth
What is Kezar Life Sciences's growth rate over time
Valuation
What is Kezar Life Sciences stock price valuation
P/E
N/A
P/B
0.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 18% year-on-year and by 13% since the previous quarter
The price to book (P/B) is 84% less than the 5-year quarterly average of 1.6 and 35% less than the last 4 quarters average of 0.4
KZR's equity is down by 38% year-on-year and by 13% since the previous quarter
KZR's revenue has dropped by 100% year-on-year
Efficiency
How efficient is Kezar Life Sciences business performance
The company's return on invested capital fell by 37% YoY
KZR's ROE is down by 28% YoY
The return on assets has declined by 22% year-on-year but it is up by 2.8% since the previous quarter
Dividends
What is KZR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KZR.
Financial health
How did Kezar Life Sciences financials performed over time
The quick ratio fell by 43% YoY and by 10% QoQ
KZR's current ratio is down by 42% year-on-year and by 12% since the previous quarter
The debt is 86% less than the equity
KZR's debt to equity is up by 40% year-on-year and by 8% since the previous quarter
KZR's equity is down by 38% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.